Skip to content

Effect of GaAlAs 940 Laser on Pain and Wound Healing After Free Gingival Graft

Single Application 940 nm GaAlAs Photobiomodulation Immediately After Free Gingival Graft Harvesting: Randomized Controlled Trial of Early Postoperative Pain and Palatal Wound Area Reduction

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07308912
Enrollment
34
Registered
2025-12-30
Start date
2024-10-01
Completion date
2025-10-01
Last updated
2026-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Level Laser Therapy, Healthy, Postoperative Pain Management, Wound Healing

Keywords

low level laser therapy, palatal donor site, free gingival harvesting, pain control, palatal wound healing, photobiomodulation

Brief summary

This randomized controlled clinical trial aims to evaluate the biomodulatory effects of a 940-nm GaAlAs diode laser on postoperative pain control and wound healing at the palatal donor site following free gingival graft harvesting. Adult patients undergoing free gingival graft surgery will be randomly allocated to receive either a single session of adjunctive diode laser irradiation immediately after surgery or sham laser irradiation without therapeutic laser energy delivery. Postoperative pain will be assessed using a visual analog scale, while clinical parameters related to wound healing, including bleeding tendency, epithelialization, and wound size reduction, will be evaluated at predefined follow-up time points. The findings of this study may contribute to the clinical understanding of photobiomodulation in free gingival graft surgery.

Interventions

A single session of 940-nm GaAlAs diode laser irradiation is applied to the palatal donor site immediately after free gingival graft harvesting using a continuous, non-contact mode (0.1 W, 4 J/cm² for 40 seconds), in combination with the use of a palatal stent.

After suturing was completed at the recipient site, sham laser irradiation was performed without therapeutic laser energy delivery, followed by placement of a palatal stent.

Sponsors

University of Medicine and Pharmacy at Ho Chi Minh City
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Periodontal surgeries are performed by a periodontist with more than 20 years of clinical experience, who is not involved in laser irradiation or clinical outcome assessment. Laser irradiation and digital scanning of the palatal wound area are performed by a trained investigator who does not participate in clinical outcome evaluation. Clinical assessments and measurements of scanned images are conducted by an independent periodontist who is blinded to group allocation.

Intervention model description

Participants were randomly assigned to two groups: a laser group receiving adjunctive 940-nm diode laser irradiation in combination with a palatal stent, and a control group receiving sham laser irradiation without therapeutic laser energy delivery in combination with a palatal stent following free gingival graft harvesting.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. ≥18 years of age; 2. systemically healthy individuals without any conditions that could affect wound healing (e.g., diabetes, immunosuppression, coagulation disorders, Candida infection; 3. full-mouth plaque score (FMPS) and full-mouth bleeding score (FMBS) \<15%; 4. no previous history of palatal tissue harvesting; 5. no use of overdentures or partial dentures covering the donor area.

Exclusion criteria

1. pregnant or breastfeeding women; 2. smokers; 3. patients with psychiatric disorders; and 4. patients taking any medications that impair tissue healing and affect pain perception.

Design outcomes

Primary

MeasureTime frameDescription
Postoperative Pain2 hours, 3 days, and 7 days after surgeryZero is equivalent to no pain and 10 indicates the worst possible pain.
Remaining Wound AreaImmediately after surgery prior to laser irradiation (baseline on day 0), and 3, 7, and 14 days after surgeryChanges in palatal donor site wound area measured using serial intraoral digital scans obtained at predefined follow-up time points

Secondary

MeasureTime frameDescription
Post-surgical Analgesic ConsumptionWithin 3 days after surgeryThe number of 500-mg acetaminophen tablets consumed by participants during the first 3 days after surgery.
Epithelialization D7Day 7Epithelialization was assessed by applying 3% hydrogen peroxide (H₂O₂) to the palatal donor site. Bubbling indicated areas without epithelial coverage. Epithelialization was classified as no epithelialization when bubbling was observed over the entire wound area, partial epithelialization when bubbling was observed over only part of the wound area, and complete epithelialization when no bubbling was observed over the wound area.
Epithelialization D14Day 14Epithelialization was assessed by applying 3% hydrogen peroxide (H₂O₂) to the palatal donor site. Bubbling indicated areas without epithelial coverage. Epithelialization was classified as no epithelialization when bubbling was observed over the entire wound area, partial epithelialization when bubbling was observed over only part of the wound area, and complete epithelialization when no bubbling was observed over the wound area.

Countries

Vietnam

Participant flow

Recruitment details

Participants were recruited from patients requiring autogenous palatal soft-tissue graft harvesting at the Faculty of Dentistry, University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam, between October 2024 and October 2025.

Baseline characteristics

Characteristic—
Age, Continuous34 Years
Palatal donor site wound area166.24 mm²
STANDARD_DEVIATION 55.94
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
Vietnam
17 Participants
Sex: Female, Male
Female
9 Participants
Sex: Female, Male
Male
8 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 170 / 16
other
Total, other adverse events
0 / 170 / 16
serious
Total, serious adverse events
0 / 170 / 16

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Oct 9, 2026